Campbell & Co Investment Adviser’s Enanta Pharmaceuticals ENTA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$508K	Sell	40,214 -13,935	-26%	-$187K	0.03%	747
2025 Q4	$854K	Buy	54,149 +35,294	+187%	+$448K	0.04%	622
2025 Q3	$226K	Buy	+18,855	New	+$151K	0.02%	987
2022 Q4	–	Sell	-13,006	Closed	-$675K	–	824
2022 Q3	$675K	Buy	+13,006	New	+$760K	0.15%	220
2022 Q1	–	Sell	-3,600	Closed	-$269K	–	749
2021 Q4	$269K	Buy	+3,600	New	+$283K	0.09%	406
2017 Q4	–	Sell	-4,709	Closed	-$220K	–	429
2017 Q3	$220K	Buy	+4,709	New	+$189K	0.18%	261

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Campbell & Co Investment Adviser's ENTA Position: Q1 2026 in Review

Campbell & Co Investment Adviser reduced its Enanta Pharmaceuticals (ENTA) stake by 26% in Q1 2026, selling an estimated $187K and leaving 40,214 shares worth $508K. The position accounts for 0.03% of the portfolio, ranked #747.

Campbell & Co Investment Adviser first reported a position in ENTA in Q3 2017 and has held it in 6 quarters since. The position peaked at $854K in Q4 2025. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

Campbell & Co Investment Adviser held 40,214 shares of Enanta Pharmaceuticals worth $508K as of Q1 2026.
Campbell & Co Investment Adviser sold 13,935 Enanta Pharmaceuticals shares in Q1 2026, an estimated $187K.
Enanta Pharmaceuticals made up 0.03% of Campbell & Co Investment Adviser's portfolio in Q1 2026, its #747 holding.
Campbell & Co Investment Adviser first reported a position in Enanta Pharmaceuticals in Q3 2017 and has held it in 6 quarters since.
Campbell & Co Investment Adviser's Enanta Pharmaceuticals position peaked at $854K in Q4 2025.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.